United Therapeutics Corporation (NASDAQ:UTHR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by on May 19th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $619.4167.

Several research analysts have issued reports on UTHR shares. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Bank of America lifted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. TD Cowen lifted their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday, March 30th. Finally, Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock.

Get Our Latest Stock Analysis on United Therapeutics

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 14,440 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $472.13, for a total value of $6,817,557.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 530,913 shares of company stock worth $294,807,957. Corporate insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Janus Henderson Group PLC raised its position in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the period. Bull Harbor Capital LLC purchased a new position in shares of United Therapeutics during the 1st quarter valued at $494,000. Strategic Investment Advisors MI grew its holdings in shares of United Therapeutics by 20.5% during the 1st quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock valued at $5,782,000 after acquiring an additional 1,662 shares in the last quarter. Talon Private Wealth LLC purchased a new position in shares of United Therapeutics during the 1st quarter valued at $3,038,000. Finally, Royal Bank of Canada grew its holdings in shares of United Therapeutics by 3.3% during the 1st quarter. Royal Bank of Canada now owns 59,152 shares of the biotechnology company’s stock valued at $35,075,000 after acquiring an additional 1,864 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $566.99 on Thursday. United Therapeutics has a 12 month low of $272.12 and a 12 month high of $609.35. The stock has a market cap of $24.07 billion, a price-to-earnings ratio of 20.93, a PEG ratio of 1.84 and a beta of 0.60. The stock’s 50 day moving average price is $559.71 and its 200 day moving average price is $508.76.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period in the previous year, the firm earned $6.63 EPS. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics will post 27.07 EPS for the current year.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Featured Stories

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.